Department of Nephrology, Peking University People's Hospital, Unit 10C in Ward Building, 11 Xizhimennan Street, Xicheng District, Beijing, 100044, China.
Division of Nephrology, Nanfang Hospital, National Clinical Research Center for Kidney Disease, State Key Laboratory of Organ Failure Research, Southern Medical University, 1838 North Guangzhou Avenue, Guangzhou, China.
Sci Rep. 2021 Jan 13;11(1):873. doi: 10.1038/s41598-020-79531-4.
The number of patients on hemodialysis (HD) is rapidly increasing in China. As an Asian country with a large number of HD patients, understanding the status of Chinese HD patients has a special significance. We reported here the baseline data for China Dialysis Outcomes and Practice Pattern Study Phase 5 (DOPPS5). The DOPPS is an international prospective, observational cohort study. Patients were restricted to the initial sample of patients who participated in China DOPPS5. We summarized the baseline demographic and clinical data of patients. Results were weighted by facility sampling fraction. 1186 patients were initial patients in China DOPPS5. The mean age was 58.7 ± 3.5 years, with 54.6% males. The median dialysis vintage was 3.4 (1.5, 6.3) years. The main assigned primary end-stage kidney disease (ESKD) causes was chronic glomerulonephritis (45.9%), followed by diabetes (19.9%). 17.6% patients had hepatitis B infection, and 10.0% patients had hepatitis C infection. 25.9% patients had a single-pooled Kt/V < 1.2. 86.6% patients had albumin > 3.5 g/dl. 18.8% patients had hemoglobin < 9 g/dl. 66.5% patients had serum calcium in target range (8.4-10.2 mg/dl), 41.5% patients had serum phosphate in target range (3.5-5.5 mg/dl) and 51.2% patients maintained PTH in 150-600 pg/dl. 88.2% patients used fistula as their vascular access. Meanwhile, there were differences in the demographic, clinical, laboratory, and treatment characteristics among the three cities participated in China DOPPS. We observed a relatively higher albumin level and a higher rate of fistula usage in our patients. But it remains a major challenge to us on the management of CKD-MBD and anemia. This study did not include patients in small cities and remote areas, where the situation of HD patients might be worse than reported.
中国接受血液透析（HD）治疗的患者数量正在迅速增加。作为一个拥有大量 HD 患者的亚洲国家，了解中国 HD 患者的现状具有特殊意义。我们在此报告中国 DOPPS5 研究的基线数据。DOPPS 是一项国际性的前瞻性观察队列研究。患者仅限于参加中国 DOPPS5 的初始样本患者。我们总结了患者的基线人口统计学和临床数据。结果按机构抽样分数加权。中国 DOPPS5 的初始患者为 1186 例。患者的平均年龄为 58.7±3.5 岁，其中 54.6%为男性。中位透析龄为 3.4（1.5，6.3）年。主要的原发性终末期肾病（ESKD）病因是慢性肾小球肾炎（45.9%），其次是糖尿病（19.9%）。17.6%的患者乙型肝炎病毒感染，10.0%的患者丙型肝炎病毒感染。25.9%的患者单池 Kt/V<1.2。86.6%的患者白蛋白>3.5g/dl。18.8%的患者血红蛋白<9g/dl。66.5%的患者血清钙在目标范围内（8.4-10.2mg/dl），41.5%的患者血清磷在目标范围内（3.5-5.5mg/dl），51.2%的患者甲状旁腺激素维持在 150-600pg/dl。88.2%的患者使用瘘管作为血管通路。同时，参与中国 DOPPS 的三个城市的患者在人口统计学、临床、实验室和治疗特征方面存在差异。我们观察到患者的白蛋白水平相对较高，瘘管使用率较高。但 CKD-MBD 和贫血的管理仍然是我们面临的主要挑战。本研究未包括小城市和偏远地区的患者，这些地区的 HD 患者情况可能比报告的更差。
